Compare Alcon AG (ALC) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Citius Pharmaceuticals Inc — how do they compare? Alcon AG trades at $66.64 (market cap $32.69B), while Citius Pharmaceuticals Inc trades at $0.56 (market cap $15.98M). The key difference: Alcon AG is far larger — about 2045.7× Citius Pharmaceuticals Inc's market cap, and Alcon AG pays a 0.54% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| ALC | CTXR | |
|---|---|---|
Market Cap | $32.69B | $15.98M |
Sector | Health | Health |
52-Week High | $92.22 | $1.94 |
52-Week Low | $62.02 | $0.53 |
Enterprise Value | $36.28B | $12.19M |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
CTXR trades at $0.6075, up 5.73% in the last session, with a neutral technical signal and bearish moving averages. The company reported a net loss of $37.43 million for 2025, with a negative net income margin of -823.34%, while generating $5.6 million in revenue in the first half of 2026 from its LYMPHIR launch. Recent news highlights positive Phase 1 data for LYMPHIR presented at ASCO, though earnings have consistently missed expectations.
The outlook remains speculative, with significant upside potential if LYMPHIR gains commercial traction, but high execution risks and persistent losses pose substantial downside. Analyst consensus is strongly bullish at 83.3% buy ratings, reflecting optimism on the drug pipeline, yet investors face dilution risks from recent financing and the challenge of achieving profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
